Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19194786 | 0.90 | KCNH2 (0.41) | KCNH2 | |
| SCHEMBL19200323 | 0.90 | KCNH2 (0.41) | KCNH2 | |
| SCHEMBL19194907 | 0.88 | KCNH2 (0.49) | KCNH2SCN5A | |
| SCHEMBL17494408 | 0.84 | KCNH2 (0.46) | KCNH2SCN5A | |
| SCHEMBL19179832 | 0.84 | KCNH2 (0.45) | KCNH2SCN5A | |
| SCHEMBL19194899 | 0.82 | KCNH2 (0.49) | KCNH2SCN5A | |
| SCHEMBL19194787 | 0.81 | KCNH2 (0.40) | KCNH2 | |
| SCHEMBL17494380 | 0.81 | KCNH2 (0.54) | KCNH2SCN5A | |
| SCHEMBL17494382 | 0.81 | KCNH2 (0.54) | KCNH2SCN5A | |
| SCHEMBL19194793 | 0.80 | KCNH2 (0.41) | KCNH2SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160726-B2 | Quinolone derivatives as antibacterials | NOVARTIS AG (CH) | 2018-12-25 | — | — | US | disclosed |
| US-20170217897-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | WUXI APPTEC (CN) | 2017-08-03 | — | — | US | disclosed |
| EP-3177593-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | Novartis AG (CH) | 2017-06-14 | — | — | EP | disclosed |
| WO-2016020836-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | NOVARTIS AG (CH) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217897-A1 | QUINOLONE DERIVATIVES AS ANTIBACTERIALS | TOP1, NQO2, TOP2A | KCNH2 3467/4885SCN5A 1288/4885 |
| US-10160726-B2 | Quinolone derivatives as antibacterials | TOP1, NQO2, TOP2A | KCNH2 3467/4885SCN5A 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.